Dr. Hiroyuki Ueno earned his PhD from Osaka University and presently serves as an officer for Kyoto University Innovation Capital. He has invested in life science and healthcare companies and has held board director or observer roles in such firms, including Chordia TX, Thyas, Drawbridge Health, AlphaNavi Pharma, Kola-Gen Pharma, and CleanHearing in the KYOTO-iCAP portfolio. His previous positions include work as a Fellow for Sumitomo Dainippon Pharmaceutical Company and Principal Scientist for Takeda Pharmaceutical Company. He is a widely published author in the fields of genetics, molecular biology, physiology, and drug discovery.